# Single Source: Pediatric Early Phase Clinical Trials Network (PEP-CTN; UM1 Clinical Trial Required)

Source: https://welltoldgrants.com/grants/rfa-ca-24-007-single-source-pediatric-early-phase-clinical-trials-network/  
Official notice: https://www.grants.gov/search-results-detail/349999

> National Institutes of Health offered grants to colleges and universities. Applications closed on November 15, 2023.

| Field | Value |
|---|---|
| Opportunity number | RFA-CA-24-007 |
| Agency | National Institutes of Health |
| Status | Forecast |
| Deadline | November 15, 2023 |
| Award ceiling | not stated |
| Award floor | not stated |
| Expected awards | not stated |
| Total funding | not stated |
| Cost sharing | not required |
| Assistance Listings | 93.395 |

## Who can apply

- Public and State controlled institutions of higher education

Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

## What the grant funds

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to enhance NCIs program for conducting early phase clinical trials in children with cancer, thereby facilitating the introduction of high priority novel agents into the pediatric oncology setting in a timely manner. This ability to quickly conduct first in children studies is critical to NCIs overall clinical research program for children with cancer. The primary scope of the Pediatric Early Phase Clinical Trials Network (PEP-CTN) is to design and conduct pediatric phase 1 trials that will often include phase 2 expansion cohorts. Conduct of the phase 2 study components within the PEP-CTN is efficient and allows intensive study monitoring for toxicity for these agents undergoing their initial evaluation in children. When phase 1 testing results for an agent are available, phase 2 studies will also be within the remit of the PEP-CTN. As well, the PEP-CTN will conduct pilot studies of novel regimens to determine their tolerability so that they can proceed to definitive testing in phase 3 clinical trials.

## Questions people ask

### Is RFA-CA-24-007 still open?

No. It closed on November 15, 2023.

### Who can apply for Single Source: Pediatric Early Phase Clinical Trials Network (PEP-CTN; UM1 Clinical Trial Required)?

National Institutes of Health accepted applications from colleges and universities. The notice adds further conditions, so read its eligibility section.

### What is the deadline for Single Source: Pediatric Early Phase Clinical Trials Network (PEP-CTN; UM1 Clinical Trial Required)?

Closed November 15, 2023. Applications are no longer accepted; the program's newer notices are on this page when there are any.

### Who has been funded under RFA-CA-24-007?

NIH RePORTER lists 1 project funded under RFA-CA-24-007 in fiscal 2024 to 2026, at 1 institution.

### Who has won Cancer Treatment Research grants before?

The largest recipients over five fiscal years were The Univeristy of Texas M.D. Anderson Cancer Center, Dana-Farber Cancer Institute, Inc., Icahn School of Medicine at Mount Sinai. The program made 3,622 awards worth $5.6 billion in that time.